10.3109/00365519609090595
10.1111/j.1528-1167.2006.00576.x
10.1111/j.1365-2710.1993.tb00586.x
10.1016/j.jchromb.2005.11.028
10.1097/00007691-199710000-00001
10.1097/00007691-200412000-00008
10.1111/j.0013-9580.2004.31203.x
10.1111/j.1528-1157.1982.tb06092.x
10.1017/S0012162206001289
Bajpai M, 1996, Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite, Drug Metab Dispos, 24, 140
10.1097/00007691-198802000-00002
10.1097/00007691-199706000-00002
10.1097/00007691-198303000-00006
10.2165/00003088-198409030-00006
10.2165/00003088-199529040-00005
10.2165/00003088-199529050-00004
10.1097/00007691-200106000-00006
10.1046/j.1528-1157.2003.62202.x
10.1016/j.eplepsyres.2004.04.006
10.1111/j.1528-1157.1983.tb04896.x
10.1097/00007691-199706000-00010
10.1111/j.0013-9580.2004.455003.x
10.1111/j.1528-1157.1987.tb03624.x
10.1111/j.1365-2125.1994.tb04375.x
10.2165/00002512-199710040-00004
10.1016/S0378-4347(00)82159-3
10.1097/00007691-200008000-00016
10.1016/S1059131102001425
10.1097/01.ftd.0000158874.54100.1a
10.1002/j.1552-4604.1986.tb03558.x
10.1111/j.1528-1157.1998.tb01356.x
10.1111/j.1528-1157.2000.tb00218.x
10.1097/00007691-200112000-00017
10.1016/S0731-7085(97)00265-3
10.1212/01.WNL.0000052997.43492.E0
10.1517/17425255.2.6.1009
10.1111/j.1749-6632.2003.tb07517.x
10.1002/j.1552-4604.1986.tb02923.x
Bockbrader HN, 2000, Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies, Neurology, 11, 412
10.1046/j.1528-1157.42.s8.7.x
10.1111/j.1528-1157.1970.tb03905.x
10.1016/S0896-6974(98)00041-3
10.1016/0002-9343(88)90054-X
10.1111/j.0013-9580.2005.55204.x
10.1016/S0140-6736(95)90581-2
10.1016/S0920-1211(99)00039-X
10.1002/j.1552-4604.1985.tb02800.x
Buchanan R, 1969, Absorption and elimination of ethosuximide in children, J Clin Pharmacol, 9, 693
Buchanan R, 1973, The absorption and excretion of ethosuximide, Int J Clin Pharmacol, 7, 213
Buchanan RA, 1996, Single‐ and multiple‐dose pharmacokinetics of zonisamide, Epilepsia, 37, 172
10.1111/j.1528-1157.1959.tb04274.x
10.1001/archneur.1960.03840120030004
Busch JA, 1998, Pregabalin (CI‐1008) single‐dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses, Epilepsia, 39, 58
10.1097/00007691-198104000-00003
10.1046/j.0306-5251.2003.01919.x
10.1002/1097-0231(20010130)15:2<159::AID-RCM210>3.0.CO;2-W
10.1016/S0022-3476(80)80705-0
10.1016/S0140-6736(00)03157-3
10.1016/S0731-7085(99)00167-3
10.1016/S0378-4347(00)00327-3
10.1097/00007691-200210000-00013
10.1212/01.WNL.0000091867.09720.6B
10.1212/01.wnl.0000240047.11166.0e
10.1111/j.1528-1167.2007.00997.x
Cloyd J, 2001, Clinical pharmacology of phenytoin in the elderly, Epilepsia, 42, 11
10.1111/j.1528-1157.1993.tb00430.x
10.1097/00007691-199912000-00004
10.1016/S0378-4347(01)00302-4
10.1097/00007691-200212000-00009
10.1097/00007691-200408000-00006
10.1016/j.jchromb.2005.09.009
Corrigan BW, 2001, Metabolic disposition of pregabalin in healthy volunteers, Clin Pharmacol Ther, 69, P18
Cramer JA, 1989, How often is medication taken as prescribed? A novel assessment technique, J Am Med Assoc, 261, 3273, 10.1001/jama.1989.03420220087032
10.1097/00007691-200112000-00012
10.1097/00007691-199602000-00016
10.1016/S0378-4347(00)81672-2
10.1097/00007691-199101000-00008
10.1212/01.WNL.0000133213.10244.FD
10.1016/S0378-4347(00)81053-1
10.1002/j.1552-4604.1982.tb05711.x
Dodson WE, 1994, Pharmacology and therapeutic aspects of antiepileptic drugs in pediatrics, J Child Neurol, 9, 1
10.1002/j.1552-4604.1996.tb04754.x
Doose DR, 2002, Antiepileptic Drugs, 727
10.1016/S0378-4347(00)83039-X
Durham SL, 1993, Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C] vigabatrin in healthy male volunteers, Drug Metab Dispos, 21, 480
10.1212/01.WNL.0000055433.55136.55
Eadie MJ, 1977, Pharmacokinetics of drugs used for petit mal 'absence' epilepsy, Clin Exp Neurol, 14, 172
10.2165/00019053-199711040-00005
10.1016/S0378-4347(00)82406-8
Easterling DE, 1988, Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans, Epilepsia, 29, 662
10.1016/j.clinthera.2005.05.010
10.1002/j.1552-4604.1976.tb01491.x
10.2165/00003495-199550040-00008
10.1016/0378-4347(92)80459-4
10.1016/0731-7085(95)01669-4
10.1097/00007691-199504000-00012
10.1111/j.1600-0404.1993.tb04106.x
10.1111/j.1365-2125.1989.tb03457.x
Fröscher W, 2002, Prospective study on concentrations‐efficacy and concentration‐toxicity correlations with lamotrigine serum levels, Epileptic Disord, 4, 49
10.1111/j.1528-1167.2006.00629.x
10.1111/j.1365-2125.1981.tb01316.x
Gardner‐Thorpe C, 1977, Antiepileptic drug monitoring
10.1111/j.1365-2125.1993.tb00422.x
10.1097/00007691-200302000-00008
10.1177/000456329503200611
10.1046/j.1365-2125.1996.03601.x
10.1111/j.1528-1157.1996.tb00576.x
10.1016/S0920-1211(00)00117-0
10.1111/j.1528-1157.1999.tb00780.x
10.1111/j.1528-1157.2000.tb02950.x
10.1177/08830738020170011301
10.1111/j.1528-1167.2007.01090.x
10.2165/00003088-199733030-00004
10.1111/j.1528-1157.1979.tb04808.x
10.1111/j.1600-0404.1983.tb04812.x
10.1111/j.1528-1157.1985.tb05675.x
10.1002/j.1875-9114.1998.tb03853.x
10.1111/j.1365-2125.1981.tb01281.x
10.1097/00007691-200302000-00009
10.1016/S0378-4347(00)80903-2
10.1016/0378-4347(92)80045-R
10.1111/j.1528-1157.1995.tb02575.x
10.1097/00007691-200202000-00016
Hamilton RA, 1981, Effects of food on valproic acid absorption, Am J Hosp Pharm, 38, 1490
10.2165/00003088-199835010-00004
10.1111/j.1365-2125.1979.tb04685.x
10.1111/j.1528-1157.1996.tb00026.x
10.1016/S0378-4347(00)84064-5
10.1111/j.1600-0404.1982.tb03106.x
10.1212/01.WNL.0000138424.33979.0C
10.1111/j.1528-1167.2007.01043.x
10.1016/S0378-4347(00)80608-8
10.1016/S0378-4347(00)83818-9
10.1111/j.1528-1157.1980.tb04081.x
Hosoda N, 1991, The long‐term effectiveness of clonazepam therapy in the control of partial seizures in children difficult to control with carbamazepine monotherapy, Jpn J Psychiatry Neurol, 45, 471
Howard JR, 1992, Effect of felbamate on carbamazepine pharmacokinetics, Epilepsia, 33, 84
10.1046/j.1365-2125.1997.00594.x
10.1046/j.1528-1157.2003.21503.x
Ito T, 1982, Pharmacokinetic studies of AD‐810, a new antiepileptic compound, Arzneimittelforschung, 32, 1581
10.1111/j.1469-8749.1974.tb03399.x
10.1111/j.1651-2227.1975.tb03873.x
10.1111/j.1528-1157.2000.tb00144.x
Johannessen SI, 1980, Antiepileptic therapy: advances in drug monitoring, 10.1097/00007691-198001000-00012
10.1097/00007691-200306000-00016
10.1111/j.1528-1167.2005.54804.x
10.2165/00003088-200645110-00002
10.1016/S0021-9673(01)94635-7
Kaibe K, 1990, Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired‐enzyme labeled antigen and antibody, Clin Chem, 37, 24
10.1016/S1059-1311(98)80074-5
10.1111/j.1365-2125.1985.tb05071.x
10.1097/00007691-199702000-00005
10.1111/j.1528-1157.1996.tb00605.x
10.1093/chromsci/37.5.145
10.1097/00007691-198905000-00002
Krämer G, 1991, Oxcarbazepine‐verapamil drug interaction study in healthy volunteers, Epilepsia, 32, 70
10.1111/j.1365-2125.1992.tb04089.x
10.1016/S0378-4347(00)00391-1
10.1001/archneur.1964.00460240074010
Kutt H, 1968, Management of epilepsy with diphenylhydantoin sodium, J Am Med Assoc, 203, 969, 10.1001/jama.1968.03140110061012
10.1097/00004714-199408000-00008
10.1016/0378-4347(93)80500-4
10.1016/S0140-6736(76)92405-3
10.1111/j.1528-1157.1991.tb05618.x
10.1111/j.1528-1157.1997.tb01734.x
10.1016/0009-9120(93)90020-7
10.1097/00007691-199706000-00009
Leppik IE, 2002, Effective levetiracetam doses and serum concentrations: age effects, Epilepsia, 43, 240
Leppik IE, 2003, Doses and serum concentrations of levetiracetam in the elderly, Epilepsia, 44, 158
10.1016/S0731-7085(01)00684-7
10.1111/j.1528-1157.1980.tb04073.x
10.1111/j.1528-1157.2000.tb00165.x
10.1016/S0378-4347(00)82190-8
10.1016/j.jchromb.2004.07.025
10.1097/00007691-200306000-00020
10.1016/S0895-4356(02)00411-0
10.2165/00003088-199936060-00006
Livingstone S, 1975, Anticonvulsant blood drug levels, J Am Med Assoc, 232, 60, 10.1001/jama.1975.03250010042028
10.1111/j.1528-1157.1994.tb05938.x
10.1001/archneur.1974.00490410037002
10.1097/00007691-198703000-00006
10.2165/00003088-198916020-00001
10.1016/S0378-4347(97)00185-0
10.1016/j.jocn.2005.12.037
10.1111/j.1528-1157.1979.tb04846.x
10.1097/00007691-199910000-00013
10.1056/NEJM198507183130303
10.1097/00007691-199610000-00001
10.1111/j.1600-0404.1996.tb00016.x
10.1097/00007691-199904000-00007
10.1097/00007691-200206000-00007
10.2165/00003088-200342120-00002
10.1097/FTD.0b013e31815d0cd5
10.1111/j.1528-1167.2006.00459.x
10.1097/FTD.0b013e318058a2c2
10.1097/00007691-199304000-00003
10.1111/j.1365-2125.1994.tb04234.x
McLean MJ, 1995, Gabapentin, Epilepsia, 36, S57
10.1097/FTD.0b013e3180683d55
Meijer JWA, 1973, Methods of analysis of anti‐epileptic drugs
10.1097/00007691-198905000-00018
10.1016/S0887-8994(03)00048-1
10.1097/00007691-200406000-00014
Mimaki T, 1992, Recent developments in therapeutic drug monitoring and clinical toxicology., 437
10.1097/00007691-199812000-00001
10.1111/j.1528-1167.2005.06805.x
Mirza Wu, 1999, Role of gabapentin levels in the control of partial seizures, Epilepsia, 40, 145
Miura H, 1993, Once daily dose of zonisamide monotherapy in the control of partial seizures in children: Clinical effects and their pharmacokinetic basis, Jpn J Ther Drug Monit, 10, 240
10.1111/j.1600-0773.1994.tb01371.x
10.1046/j.1365-2125.1998.00835.x
Naito H, 1988, Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by overdose of the drugs, Curr Ther Res, 43, 463
10.1002/j.1552-4604.1982.tb02662.x
Noguchi H, 1988, Simultaneous HPLC determination of zonisamide and other antiepileptic drugs in human serum, Jpn Pharmacol Ther, 16, 4805
10.1097/00007691-198409000-00018
10.1111/j.1528-1157.2000.tb00232.x
Ohman I, 2007, Plasma concentrations of lamotrigine and its 2‐N‐glucuronide metabolite during pregnancy in women with epilepsy, Epilepsia
10.1097/00007691-198712000-00001
10.1016/S0022-3476(78)80034-1
10.1016/S0140-6736(85)90420-9
10.1016/S0140-6736(87)93069-8
10.1111/j.1365-2125.1990.tb03682.x
10.1177/000456329903600102
Patsalos PN, 1995, The pharmacology and pharmacokinetics of vigabatrin, Rev Contemp Pharmacother, 6, 447
10.1016/S0163-7258(99)00052-2
Patsalos PN, 2002, Concentration‐dependent displacement of tiagabine by valproic acid, Epilepsia, 43, 143
10.1016/S1474-4422(03)00409-5
10.1016/S1474-4422(03)00483-6
10.2165/00003088-200443110-00002
Patsalos PN, 2004, Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions, Rev Contemp Pharmacother, 13, 1
Patsalos PN, 2005, Anti‐epileptic drug interactions. A clinical guide
10.1111/j.1528-1167.2006.00819.x
10.2165/00002018-199921030-00006
10.1046/j.1528-1157.2001.41300.x
10.1212/WNL.61.6_suppl_2.S35
10.1212/01.WNL.0000103286.47129.F8
Pennell PB, 2007, Lamotrigine in pregnancy, Neurology
Penovich PE, 1997, Clinical experience with topiramate: correlation of serum levels with efficacy and adverse effects, Epilepsia, 38, 181
10.1097/00007691-198002040-00005
Perucca E, 1981, Therapeutic drug monitoring, 320
10.1177/014107688107400606
10.2165/00003088-198400091-00009
10.1111/j.1365-2125.1984.tb02401.x
10.1111/j.1365-2125.1984.tb02482.x
10.2165/00003088-198510060-00003
10.1016/0163-7258(87)90096-9
10.2165/00003088-199631010-00003
10.1111/j.1528-1157.1998.tb01268.x
10.1111/j.1528-1157.1999.tb02088.x
10.2165/00003088-200038030-00001
10.2165/00023210-200115080-00004
10.2165/00023210-200216100-00004
10.1016/S0920-1211(02)00182-1
10.1016/S0920-1211(02)00250-4
10.1111/j.1528-1167.2005.463007.x
10.2165/00003088-200645040-00002
10.1016/j.eplepsyres.2005.07.017
10.1111/j.1528-1167.2006.00871.x
10.1111/j.1528-1167.2008.01665.x
10.1016/S0378-4347(00)80886-5
Pippenger CE, 1978, Antiepileptic drugs: quantitative analysis and interpretation
10.1111/j.1528-1157.1984.tb04180.x
10.1111/j.1528-1157.1990.tb05385.x
10.1111/j.1600-0404.1994.tb02692.x
Pokrajac M, 1992, An improved gas chromatographic determination of valproic acid and valpromide in plasma, Pharma Acta Helvetica, 67, 237
10.1177/106002808702100306
10.1111/j.1365-2125.1991.tb03907.x
10.1093/chromsci/40.4.219
Ragueneau‐Majlessi I, 2002, Antiepileptic Drugs, 581
10.2165/00003088-199325060-00003
Ramsay RE, 1994, Effect of age on epilepsy and its treatment: results of the VA Cooperative Study, Epilepsia, 35, 9
10.1212/WNL.62.5_suppl_2.S24
10.1097/00007691-199009000-00010
10.1097/00007691-199604000-00008
10.1097/00007691-199808000-00013
Reife RA, 1995, Topiramate PK/PD analysis, Epilepsia, 36, S152
Retzow A, 1997, Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation, Arzneimitteelforschung, 47, 1347
10.1111/j.1365-2125.1990.tb03772.x
10.2165/00003088-199223040-00003
10.2165/00003088-197904030-00001
Richens A, 1993, New trends in epilepsy management: the role of gabapentin, 41
Richens A, 1995, Quality control of drug estimates, Acta Neurol Scand, 60, 81
10.1016/S0731-7085(98)00137-X
10.2165/00003088-199631060-00005
10.1097/00007691-199402000-00015
10.1111/j.1528-1157.1997.tb01124.x
10.1016/S0887-8994(99)00011-9
10.1016/0378-4347(95)00026-F
10.1212/01.WNL.0000167384.68207.3E
10.1111/j.1365-2125.1979.tb04665.x
10.1592/phco.23.15.1550.31957
10.1097/00007691-200302000-00009
10.1212/01.WNL.0000076485.09353.7A
Sachdeo RC, 1993, Steady‐state pharmacokinetics and dose‐proportionality of felbamate after oral administration of 1200, 2400, and 3600 mg/day of felbamate, Epilepsia, 34, 80
10.1111/j.1528-1157.1996.tb00651.x
10.1111/j.1528-1167.2007.01128.x
10.1097/00007691-199404000-00011
10.1111/j.1365-2125.1989.tb03456.x
10.1001/archneur.1986.00520030053013
10.1007/978-3-642-85921-2
10.1016/0378-4347(93)80469-K
10.3109/00498258609043567
10.1097/00007691-199208000-00002
10.1016/S1570-0232(02)00119-8
10.1001/archneur.1973.00490210058007
10.1016/S0021-9673(03)00716-7
10.1002/(SICI)1099-0801(199908)13:5<370::AID-BMC900>3.0.CO;2-5
Shorvon SD, 1980, Antiepileptic therapy: Advances in drug monitoring, 213
Shumaker RC, 1990, Evaluation of the elimination of (14C) felbamate in healthy men, Epilepsia, 31, 642
10.1111/j.1365-2125.2005.02539.x
10.1111/j.1528-1157.1991.tb04689.x
10.1016/0920-1211(95)00048-8
10.1016/S0378-4347(96)00215-0
10.1016/S1525-5050(03)00151-3
10.1097/00007691-199103000-00004
10.1111/j.1528-1157.2000.tb00282.x
10.1177/009127000004001216
10.1097/00007691-199107000-00010
10.1016/j.eplepsyres.2006.01.011
10.1097/00007691-199704000-00006
10.1016/0378-4347(96)00121-1
10.1046/j.1365-2710.1999.00201.x
10.1097/00007691-200004000-00010
Taylor C, 1986, New anticonvulsant drugs, 277
10.1056/NEJM199301073280105
10.1177/088307389701200311
10.1111/j.1528-1157.1999.tb00777.x
Tompson DJ, 2007, Steady‐state pharmacokinetics of lamotrigine when converting from a twice‐daily immediate‐release to a once‐daily extended‐release formulation in subjects with epilepsy (The COMPASS Study), Epilepsia
10.1111/j.1528-1157.1994.tb02921.x
10.1111/j.1528-1157.1997.tb01489.x
10.1212/01.wnl.0000238522.79277.9c
Tomson T, 2007, Therapeutic monitoring of antiepileptic drugs for epilepsy, Cochrane Database Syst Rev, 1, CD002216
10.1111/j.1528-1167.2007.01032.x
Twyman RE, 1999, Plasma topiramate (TPM) concentration vs. therapeutic response during monotherapy, Epilepsia, 40, 111
Van Parys JAP, 1994, Survey of 260 patients treated with oxcarbazepine (Trileptal) on a named‐patient basis, Epilepsy Res, 84, 224
10.1046/j.1365-2125.1996.31610.x
10.1016/0378-4347(94)00393-9
10.1016/S0378-4347(98)00269-2
Vermeij TA, 2004, Simultaneous high‐performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with 0‐phthadialdehyde and fluorescence detection, J Chromatogr B Analyt Technol Biomed Life Sci, 810, 297, 10.1016/S1570-0232(04)00662-2
10.1002/j.1552-4604.1978.tb02428.x
Vollmer KO, 1988, Pharmacokinetics and metabolism of gabapentin in rat, dog and man, Arzneim Forsch Drug Res, 36, 830
Volosov A, 1999, Enantioselective pharmacokinetics of 10‐hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects, Clin Pharmacol Ther, 66, 547, 10.1053/cp.1999.v66.103170001
10.1016/S0378-4347(99)00531-9
10.1111/j.1365-2125.1979.tb04664.x
10.1016/0378-4347(85)80136-5
10.1016/S0378-4347(97)00521-5
10.1111/j.1528-1157.1991.tb04669.x
WallMS CoxM VoorsJ OuyangA ArabshahiL. (2006)A new QMS lamotrigine assay on the Hitachi 917 system.Poster presented at the 60th Annual Meeting of the American Epilepsy Society San Diego CA .
10.1016/0387-7604(94)90108-2
10.1097/00007691-199602000-00001
Wang X, 2002, The pharmacokinetic profile of tiagabine, Rev Contemp Pharmacother, 12, 225
Ward DL, 1990, Comparative bioavailability of felbamate in healthy men, Epilepsia, 31, 642
Ward DL, 1991, Felbamate steady‐state pharmacokinetics during co‐administration of valproate, Epilepsia, 32, 8
10.2165/00023210-200115020-00005
Whyte MP, 1977, Metabolic fate of phenobarbital, Drug Metab Dispos, 5, 63
10.1111/j.1528-1157.1985.tb05699.x
10.1046/j.1528-1157.2003.26702.x
10.1097/00007691-198903000-00011
10.1097/00007691-199204000-00004
10.1016/S0920-1211(97)00078-8
10.1111/j.1528-1157.1988.tb04408.x
Woodbury DM, 1972, Antiepileptic drugs.
Yerby MS., 1992, Antiepileptic drug disposition during pregnancy, Neurology, 42, 12
Zavadil P, 1976, Epileptology, 129
10.1016/j.jchromb.2006.01.018
